Dendrite Clinical Systems and the Society for Cardiothoracic surgery (SCTS) have published a new report that demonstrates importance collecting and analysing data from thoracic surgery. The report states that a large increase in thoracoscopic (VATS) resections is responsible for most of the recent increase in lung cancer surgery, rising from 749 cases in 2010-2011 to 2,753 in 2014-2015, an increase of more than 3.5 times.
Dendrite Clinical Systems is to install its Intellect System to track outcomes of cardiothoracic surgery at St George’s Hospital, Tooting, London, UK. The company’s data capture software currently supports approximately 85% of cardiac units in the UK. 
Dendrite Clinical Systems and Waldenström’s Macroglobulinaemia United Kingdom Charity have published the First UK Waldenström’s Macroglobulinaemia Registry Report 2018 – the first report of its kind in the world. 
Dendrite Clinical Systems, the publisher of Bariatric News, is pleased to announce issue 38 of the newspaper is now available to view/download. The newspaper reports on research, technology, events and policy in the bariatric specialty, the latest clinical studies, policy changes and product news, the latest meetings and events, interviews prominent bariatric experts, and host debates between specialists on controversial topics.
Dendrite Clinical Systems, under the auspices of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), has published the Fourth IFSO Global Registry Report (2018) at the federation’s XXIII World Congress in Dubai, UAE. The latest report features data from more than 50 countries on over 394,000 operations including baseline obesity-related disease, operation types, operative outcomes and disease status after bariatric/metabolic surgery.
Dendrite and BSACI launch BRIT immunotherapy registry
Dendrite Clinical Systems and the British Society for Allergy & Clinical Immunology (BSACI) have launched the British Registry for Immunotherapy (BRIT), a web-based patient registry that records immunotherapy treatment of patients under the care of BSACI consultants practicing in the UK.
“We are delighted to launch the first national immunotherapy registry in the UK,” said Dr peter Walton, managing Director of Dendrite Clinical Systems. “By recording each and every serious adverse event during immunotherapy treatment, the BSACI we will be able to monitor the efficacy of immunotherapy enabling the BSACI to guide commissioning of services and guideline development.”
BRIT is a secure web-based registry that can record the use of Allergen Immunotherapy (AIT) by both subcutaneous and sublingual immunotherapy routes (also known as SCIT and SLIT). By venom immunotherapy (VIT) and the use of the monoclonal antibody Omalizumab (OMA) for Chronic Spontaneous Urticaria (CSU) in patients under the care of BSACI registered consultants. It will help consultants keep track of their patients and monitor their response to treatment by using email PROM reported directly by participants. It will also monitor safety and access to treatment around the UK.
To better understand what the current practises are in the UK, an online registry was developed by Dendrite using their “Intellect Web” software. This allows consultants to enter patient data online, using a range of modern html-5 compatible web browsers, without the need to install additional software or perform any complex system configurations.
The registry is open for all consultant BSACI members to register their practice(s) for both adult and paediatric patients. Additional healthcare professionals in the practice can register as users under the same practice in order to input data into the registry.
The registry is funded by unrestricted grants from three companies: AlK Abello, Allergy Therapeutics and Stallergenes.
